Jim J Xiao

Summary

Publications

  1. ncbi Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys
    Jim J Xiao
    Amgen, Thousand Oaks, California 91320, USA
    AAPS J 12:646-57. 2010
  2. ncbi Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects
    Yow Ming C Wang
    Pharmacokinetics and Drug Metabolism Department, Amgen Inc, Thousand Oaks, California 91320, USA
    AAPS J 12:729-40. 2010

Detail Information

Publications2

  1. ncbi Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys
    Jim J Xiao
    Amgen, Thousand Oaks, California 91320, USA
    AAPS J 12:646-57. 2010
    ..Additionally, the total amount of FcRn receptor involved in Ab 12B9m recycling at a given time was calculated empirically, and the temporal changes in the free FcRn levels upon Ab 12B9m administration were inferred...
  2. ncbi Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects
    Yow Ming C Wang
    Pharmacokinetics and Drug Metabolism Department, Amgen Inc, Thousand Oaks, California 91320, USA
    AAPS J 12:729-40. 2010
    ..Thus, the mechanistic PK-PD model was suitable for describing the romiplostim PK-PD interplay (PDMDD), the dose-dependent platelet stimulation, and the lifespans of thrombopoietic cell populations...